Summary
In Kyoto University Hospital, stereotactic radiosurgery (SRS) has been performed for its rapid palliative effect in patients with recurrent primary central nervous system lymphoma (PCNSL), often in combination with salvage chemotherapy. In the present study, the treatment outcome and toxicity of SRS for recurrent PCNSL was retrospectively evaluated. Between March 1998 and June 2004, 17 histologically proven recurrent PCNSLs in nine patients were treated with linac-based stereotactic radiosurgery. All patients had developed intracranial recurrences after initial treatment including external beam radiation therapy (EBRT). The prescribed dose was 10.0–16.0 (median 12.0) Gy. Seven of nine patients received systemic chemotherapy around the time of SRS. The target volume was 0.4–24.5 ml (median 3.5 ml). Initial tumor response could be evaluated in 15 of 17 lesions. Among them, radiological complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) was observed in 3, 10, 2, and 0 lesions, respectively. One-year overall survival rate and relapse-free survival rate after first SRS was 58% and 22%, respectively. Improvement of symptoms was observed in six patients. The time from SRS to symptomatic relief was 1–57 days (median 3 days). No ≥ grade 2 acute toxicities related to SRS were observed. In conclusion, linac-based SRS with a prescription dose of 10–12 Gy for recurrent PCNSL is useful for palliation, especially considering the short time, rapid tumor response, and low treatment toxicity.
Similar content being viewed by others
References
HA Fine and RJ Mayer, Primary central nervous system lymphoma. Ann Intern Med 119 (1993) 1093-1104
SR Plotkin and TT Batchelor, Primary nervous-system lymphoma. Lancet Oncol 2 (2001) 354-365
AJ Ferreri, LE Abrey, JY Blay, B Borisch, J Hochman, EA Neuwelt, J Yahalom, E Zucca, F Cavalli, J Armitage and T Batchelor, Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21 (2003) 2407-2414
GA Sanden van den, LJ Schouten, JA Dijck van, JP Andel van, RW Maazen van der and JW Coebergh, Working Group of Specialists in Neuro-Oncology in the Southern, Eastern Netherlands: Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 94 (2002) 1548-1556
H Ishikawa, M Hasegawa, Y Tamaki, K Hayakawa, T Akimoto, H Sakurai, N Mitsuhashi, H Niibe, M Tamura and T Nakano, Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma. Jpn J Clin Oncol 33 (2003) 443-449
Y Shibamoto, E Tsuchida, K Seki, N Oya, M Hasegawa, Y Toda, M Takemoto, M Sumi, J Hiratsuka, M Oguchi, M Hosono, S Yasuda, M Sougawa, Y Kakutoh and N Hayabuchi, Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 130 (2004) 351-356
EM Bessell, A Lopez-Guillermo, S Villa, E Verger, B Nomdedeu, J Petit, P Byrne, E Montserrat and F Graus, Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 (2001) 231-236
EM Bessell, F Graus, A Lopez-Guillermo, S Villa, E Verger, J Petit, I Holland and P Byrne, CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 50 (2001) 457-464
T Cheng, P Forsyth, A Chaudhry, D Morris, S Gluck, JA Russell and DA Stewart, High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 (2003) 679-685
PM Poortmans, HC Kluin-Nelemans, H Haaxma-Reiche, M Van't Veer, M Hansen, P Soubeyran, M Taphoorn, J Thomas, M Bent Van den, M Fickers, G Imhoff Van, C Rozewicz, I Teodorovic and M Glabbeke van, European Organization for Research, Treatment of Cancer Lymphoma Group: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 (2003) 4483-4488
T Watanabe, Y Katayama, A Yoshino, C Komine, T Yokoyama and T Fukushima, Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 63 (2003) 87-95
L Plasswilm, U Herrlinger, A Korfel, M Weller, W Kuker, L Kanz, E Thiel and M Bamberg, Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 81 (2002) 415-423
Y Shibamoto, N Hayabuchi, J Hiratsuka, S Tokumaru, H Shirato, M Sougawa, N Oya, Y Uematsu and M Hiraoka, Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97 (2003) 128-133
M Reni, AJ Ferreri and E Villa, Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79 (1999) 530-534
M Reni and AJ Ferreri, Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80 (2001) B113-117
E Arellano-Rodrigo, A Lopez-Guillermo, EM Bessell, B Nomdedeu, E Montserrat and F Graus, Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70 (2003) 219-224
Radiation Therapy Oncology Group: RTOG 95-07 Phase I Study OF Topotecan Plus Cranial Radiation for Glioblastoma Multiforme (NSC #609699) Appendix II Neurologic Function (NF) Status
Y Dong, L Pan, B Wang, E Wang, N Zhang, P Cai and J Dai, Stereotactic radiosurgery in the treatment of primary central nervous system lymphoma. Chin Med J (Engl) 116 (2003) 1166-1170
RM Tyson, T Siegal, ND Doolittle, C Lacy, DF Kraemer and EA Neutwelt, Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44 (2003) 627-633
SL Stafford, BE Pollock, RL Foote, DA Gorman, DF Nelson and PJ Schomberg, Stereotactic radiosurgery for recurrent ependymoma. Cancer 88 (2000) 870-875
RS Hudes, BW Corn, M Werner-Wasik, D Andrews, J Rosenstock, L Thoron, B Downes and WJ Curran Jr, A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43 (1999) 293-298
E Alexander III and JS Loeffler, Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14 (1998) 43-52
JM Varlotto, JC Flickinger, A Niranjan, AK Bhatnagar, D Kondziolka and LD Lunsford, Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57 (2003) 452-464
C Soussain, F Suzan, K Hoang-Xuan, N Cassoux, V Levy, N Azar, C Belanger, E Achour, V Ribrag, S Gerber, JY Delattre and V Leblond, Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749
M Reni, W Mason, F Zaja, J Perry, E Franceschi, D Bernardi, S Dell’Oro, C Stelitano, M Candela, A Abbadessa, A Pace, R Bordonaro, G Latte, E Villa and AJ Ferreri, Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40 (2004) 1682-1688
RH Enting, A Demopoulos, LM Angelis De and LE Abrey, Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakamoto, M., Oya, N., Mizowaki, T. et al. Initial Experiences of Palliative Stereotactic Radiosurgery for Recurrent Brain Lymphomas. J Neurooncol 77, 53–58 (2006). https://doi.org/10.1007/s11060-005-7698-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-7698-8